Phase I studies of anti-ENPP3 antibody drug conjugates (ADCs) in advanced refractory renal cell carcinomas (RRCC).

Volume: 33, Issue: 15_suppl, Pages: 2503 - 2503
Published: May 20, 2015
Abstract
2503 Background: ENPP3 is expressed in greater than 90% of clear cell (CC) and 70% of papillary (PAP) RCC and represents an interesting target in this disease. Hybridoma-derived AGS-16M8F and...
Paper Details
Title
Phase I studies of anti-ENPP3 antibody drug conjugates (ADCs) in advanced refractory renal cell carcinomas (RRCC).
Published Date
May 20, 2015
Volume
33
Issue
15_suppl
Pages
2503 - 2503
Citation AnalysisPro
  • Scinapse’s Top 10 Citation Journals & Affiliations graph reveals the quality and authenticity of citations received by a paper.
  • Discover whether citations have been inflated due to self-citations, or if citations include institutional bias.